腎癌患者における尿中インターロイキン1β, インターロイキン6, 腫瘍壊死因子-αの検討

Abstract

1)腎細胞癌患者の腎癌摘除前尿中IL-1β濃度は進行度や組織異型度による差はなく, 又, 対照群に比べて有意差を認めなかった.腎細胞癌患者の術後尿中IL-1β濃度は有意に上昇したが, 一定の傾向は認めなかった. 2)腎細胞癌患者の尿中IL-6とTNF-αは術前後とも測定可能例が少なく, 対照群に比べ有意差を認めなかった.以上より尿中IL-1β, IL-6, TNF-αの測定は腎細胞癌の診断に臨床的有用性は低いと考えられた

We examined the preoperative and postoperative, urinary levels of the cytokines, interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in 14 patients with renal cell carcinoma (RCC), and 9 patients who underwent nephrectomy as donors (controls). Although urinary IL-1 beta was measurable in every subject, both IL-6 and TNF-alpha were undetectable in 12 of the 14 patients. None of the urinary cytokines showed levels significantly different from the controls preoperatively. Urinary levels of IL-1 beta showed no correlation with clinical stage or histological grade. Only urinary IL-1 beta was significantly elevated after nephrectomy, when compared with the controls (P < 0.05). However, urinary IL-1 beta showed no correlation with operative blood loss or postoperative infection. These findings suggest that measurement of urinary cytokines is not useful for diagnosis or monitoring of therapy in RCC patients.